These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26810861)

  • 1. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.
    Chairat K; Jittamala P; Hanpithakpong W; Day NP; White NJ; Pukrittayakamee S; Tarning J
    Br J Clin Pharmacol; 2016 Jun; 81(6):1103-12. PubMed ID: 26810861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
    Pai MP; Lodise TP
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5640-5. PubMed ID: 21930881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.
    Jittamala P; Pukrittayakamee S; Tarning J; Lindegardh N; Hanpithakpong W; Taylor WR; Lawpoolsri S; Charunwattana P; Panapipat S; White NJ; Day NP
    Antimicrob Agents Chemother; 2014; 58(3):1615-21. PubMed ID: 24366750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.
    Pillai VC; Han K; Beigi RH; Hankins GD; Clark S; Hebert MF; Easterling TR; Zajicek A; Ren Z; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2015 Nov; 80(5):1042-50. PubMed ID: 26040405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).
    Thorne-Humphrey LM; Goralski KB; Slayter KL; Hatchette TF; Johnston BL; McNeil SA;
    J Antimicrob Chemother; 2011 Sep; 66(9):2083-91. PubMed ID: 21700623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
    Kamal MA; Van Wart SA; Rayner CR; Subramoney V; Reynolds DK; Bulik CC; Smith PF; Bhavnani SM; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3470-7. PubMed ID: 23669384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.
    Mulla H; Peek GJ; Harvey C; Westrope C; Kidy Z; Ramaiah R
    Anaesth Intensive Care; 2013 Jan; 41(1):66-73. PubMed ID: 23362894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
    Kongpatanakul S; Chatsiricharoenkul S; Panich U; Sathirakul K; Pongnarin P; Sangvanich P
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):654-62. PubMed ID: 19049700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
    Parrott N; Davies B; Hoffmann G; Koerner A; Lave T; Prinssen E; Theogaraj E; Singer T
    Clin Pharmacokinet; 2011 Sep; 50(9):613-23. PubMed ID: 21827216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
    Deleu S; Kakuda TN; Spittaels K; Vercauteren JJ; Hillewaert V; Lwin A; Leopold L; Hoetelmans RMW
    Br J Clin Pharmacol; 2018 Nov; 84(11):2663-2672. PubMed ID: 30098042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.
    Kamal MA; Lien KY; Robson R; Subramoney V; Clinch B; Rayner CR; Gibiansky L
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6774-81. PubMed ID: 26282419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.
    Beigi RH; Han K; Venkataramanan R; Hankins GD; Clark S; Hebert MF; Easterling T; Zajicek A; Ren Z; Mattison DR; Caritis SN;
    Am J Obstet Gynecol; 2011 Jun; 204(6 Suppl 1):S84-8. PubMed ID: 21492826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
    Deng R; She G; Maia M; Lim JJ; Peck MC; McBride JM; Kulkarni P; Horn P; Castro A; Newton E; Tavel JA; Hanley WD
    J Clin Pharmacol; 2020 Nov; 60(11):1509-1518. PubMed ID: 32621543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
    Chen Y; Ke M; Xu J; Lin C
    AAPS PharmSciTech; 2020 Mar; 21(3):98. PubMed ID: 32128656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.
    Jullien V; Hubert D; Launay O; Babany G; Lortholary O; Sermet I
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4183-7. PubMed ID: 21670188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.
    Gibiansky L; Giraudon M; Rayner CR; Brennan BJ; Subramoney V; Robson R; Kamal MA
    J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):225-36. PubMed ID: 25821064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oseltamivir and oseltamivir carboxylate concentrations in venous plasma, venous blood, and capillary blood in healthy volunteers.
    Instiaty I; Lindegardh N; Jittmala P; Hanpithakpong W; Blessborn D; Pukrittayakamee S; White NJ; Tarning J
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2858-62. PubMed ID: 23507284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.
    Gibiansky L; Ravva P; Parrott NJ; Bhardwaj R; Zwanziger E; Grimsey P; Clinch B; Sturm S
    Clin Pharmacol Ther; 2020 Jul; 108(1):126-135. PubMed ID: 31957010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.